Phormulate Consulting Limited

DRUG PRODUCT DESIGN - DEVELOPMENT SUPPORT - EXPERT ADVICE

PUBLICATIONS

Book Chapters

Houghton RJ, Feely LC, Sims EE, Watts PJ, Davies MC. Other types of multiparticulate dosage forms. Ch. 5 in Multiparticulate oral dosage forms: Technology and biopharmaceutics. Melia C, Washington N and Wilson CG (eds), Scottish Academic Press, 1994

Watts P, Smith A, Hinchcliffe M. ChiSys as a chitosan-based delivery platform for nasal vaccination. Ch 23 in Mucosal delivery of biopharmaceuticals: biology, challenges and strategies. Das Neves J and Sarmento B (eds), Springer, 2014

Papers

Irwin WJ, MacHale R, Watts PJ. Drug delivery by ion-exchange. Part VII. Release of acidic drugs from anionic exchange resinate complexes. Drug Dev. Ind. Pharm. 1990; 16: 883-898

Watts PJ, Melia CD, Davies MC. Microencapsulation using emulsification-solvent evaporation: An overview of techniques and applications. Crit. Rev. Ther. Drug Carr. Sys. 1990; 7: 235-259

Watts PJ, Davies MC, Melia CD. Encapsulation of 5-aminosalicylic acid into Eudragit RS microspheres and modulation of their release characteristics by use of surfactants. J. Control. Rel. 1991; 16: 311-318,

Watts PJ, Tudor A, Church SJ, Hendra PJ, Melia CD, Davies MC. Fourier Transform Raman Spectroscopy for the qualitative and quantitative characterisation of sulfasalazine-containing polymeric microspheres. Pharm. Res. 1991: 8; 1323-1328

Watts PJ, Atkin BP, Wilson CG, Davies MC, Melia CD. Radiolabelling of polymer microspheres for scintigraphic investigations by neutron activation. 1. Incorporation of samarium oxide and effects on the properties of Eudragit RS:sulphasalazine microspheres. Int. J. Pharm. 1991: 76; 55-59

Barrow L, Steed KP, Watts PJ, Melia CD, Davies MC, Wilson CG, Spiller RC. Scintigraphic demonstration of lactulose-induced accelerated proximal colonic transit. Gastroenterology 1992; 103: 1167-1173

Watts PJ, Barrow L, Steed KP, Davies MC, Melia CD, Spiller RC, Wilson CG. Transit rate of different-sized model dosage forms through the colon and the effects of a lactulose-induced catharsis. Int. J. Pharm. 1992; 87: 215-221

Barrow L, Steed KP, Spiller RC, MaskelL NA, Brown JK, Watts PJ, Melia CD, Davies MC, Wilson CG. Quantitative non-invasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in man. Dig. Dis. Sci. 1993: 38; 996-1003

Watts PJ, Wilson CG, Davies MC, Melia CD. Radiolabelling of polymer microspheres for scintigraphic investigations by neutron activation. 2. Effects of irradiation on the properties of Eudragit RS-sulphasalazine microspheres. Int. J. Pharm. 1993; 98: 63-73

Watts PJ, Wilson CG, Davies MC, Melia CD. Radiolabelling of polymer microspheres for scintigraphic investigations by neutron activation. 3. Samarium oxide incorporation changes physical properties of sulphapyridine-Eudragit RS microspheres. Int. J. Pharm. 1993; 98: 75-82

Watts PJ, Wilson CG, Davies MC, Melia CD. Radiolabelling of polymer microspheres for scintigraphic investigations by neutron activation. 4. A pharmacoscintigraphic evaluation of colon-targeted sulphapyridine-Eudragit RS microspheres in man. Int. J. Pharm. 1994; 102: 101-108

Richardson JL, Whetstone J, Fisher AN, Watts P, Farraj NF, Hinchcliffe M, Benedetti L, Illum L Gamma scintigraphy as a novel method to study the distribution and retention of a bioadhesive vaginal delivery system in sheep. J. Control. Rel. 1996: 42; 133-142

Washington N, Ridley P, Thomas C, Spiller RC, Watts PJ, Wilson CG. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea. Aliment. Pharmacol. Ther. 1998; 12: 583-588

Watts PJ, Illum L. Colonic Drug Delivery. Drug Dev. Ind. Pharm. 1997; 23: 893-913

Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, Illum L, Davis SS, Wood JM, Major D, Minor PD, Li X, Lavelle EC, Coombes AGA. Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 2000; 18: 238-250

Illum L, Watts P, Fisher AN, Jabbal-Gill I, Davis SS. Novel chitosan-based delivery systems for nasal administration of goserelin. STP Pharma 2000; 10: 89-94

Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 2002; 301: 391-400

Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Illum L. Nasal delivery of insulin using novel chitosan-based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm. Res. 2002; 19: 998-1008

Watts P, Smith A. TARGIT™ technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin. Drug Deliv. 2005; 2: 159-167

Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, Watts P. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur. J. Pharm. Sci. 2005; 26: 9-15

Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin. Drug Deliv. 2009; 6: 543-52

Watts P, Smith A. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? Drug Discovery Today 2011; 16: 4-7

Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin. Drug Deliv. 2012; 9: 1051-67

Castile J, Simmons B, Cheng YH, Smith A, Perelman M, Watts P. Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip. Drug Dev. Ind. Pharm. 2013; 39: 816-24

Watts P, Smith A, Perelman M. Nasal delivery of fentanyl. Drug Deliv. Transl. Res. 2013; 3: 7583

Capel V, Vllasaliu D, Watts P, Clarke PA, Luxton D et al. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA. Drug Delivery 2018, 25: 644-653